The phase III VIALE-A study demonstrated that Venclexta in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukemia who were ineligible for intensive induction chemotherapy, compared to azacitidine alone.
Highly focused, intense doses of radiation called stereotactic ablative radiation may slow progression of disease in a subset of men with hormone-sensitive prostate cancers that have spread to a few separate sites in the body, according to results of a phase II clinical trial of the therapy.
Repurposed antidepressant may be a treatment option when prostate cancer comes back, USC study finds
An antidepressant in use for decades, repurposed to fight prostate cancer, shows promise in helping patients whose disease has returned following surgery or radiation, a pilot study at USC shows.
A study conducted by researchers at MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor activity in patients with four types of advanced, hard-to-treat rare cancers. Study findings were published in the March 17 online issue of the Journal for ImmunoTherapy of Cancer.
A combination of body mass index and levels of albumin, a protein made by the liver, can predict how well older adults with cancer will be able to tolerate the side effects of chemotherapy, according to a study led by a researcher at Fox Chase Cancer Center.
Advances in treatment have led to the largest yearly declines in deaths due to melanoma ever recorded for this skin cancer, results of a study suggest.
FDA issued a draft guidance document, “Inclusion of Older Adults in Cancer Clinical Trials Guidance for Industry,” to provide recommendations to sponsors and institutional review boards for the inclusion of older adult patients, ages 65 years and older, in the clinical trials of drugs for the treatment of cancer.
The phase III GY004 trial examining primarily the efficacy and safety of investigational medicine cediranib in combination with Lynparza versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer failed to meet its primary endpoint of progression-free survival.
Patients who used copper intrauterine devices were found to have a lower risk of high-grade cervical neoplasms compared to users of the levonorgestrel-releasing intrauterine system, according to a Columbia study recently published in Obstetrics & Gynecology.
Five-year survival rates have improved for young adults with cancer, according to a studyin the Journal of the National Cancer Institute. For some cancers, however, there has been little improvement since the 1970s.
